Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 173 companies reached new 52-week lows.
Cramer Weighs In On RealReal, Affirm Holdings And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said no to RealReal Inc (NASDAQ: REAL). He is not a buyer because there are too many of these guys.
MindMed Reports Q2 Earnings With Net Loss of $36M And Cash Balance Of $157M To Continue With Its Clinical Pipeline
The psychedelics-focused medicines company MindMed (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ), announced its second-quarter financial results Friday with a net and comprehensive loss of $36 million, which compares to a loss of $14 million in the previous qua
What Do You Really Know About Psychedelics And Psychedelics Stocks?
According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use.
HC Wainwright & Co. Initiates Coverage On Mind Medicine with Buy Rating, Announces Price Target of $10
HC Wainwright & Co. analyst Patrick Trucchio initiates coverage on Mind Medicine (NASDAQ:MNMD) with a Buy rating and announces Price Target of $10.
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Psilocybin Alpha.
In just a couple of years, psychedelics took the world of investing by storm.
MindMed Leverages Ayahuasca’s Ingredient DMT In Psychedelic-Inspired Therapies, Launches Trials With 30 Subjects
Psychoactive brew ayahuasca is known for having a fast-onset antidepressant effect.
With serotonergic psychedelics, such as ayahuasca, giving promising results in the quest for alternative treatments for depression and anxiety, many companies are turning their focus to developing psychedelic-inspired therapies.
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To “Psychedelics Renaissance”
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector.
Psyched: Numinus, MindMed, Cybin Reach Milestones, Harvard To Study Psychedelics Law, Michael Pollan Dives Into Mescaline
Michael Pollan’s New Book Takes A Deep Dive Into Mescaline – Will This Be A Turning Point For The Recognition And Study of Mescaline?